We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
A New, Longer-Lasting Type of Cholera Vaccine
News

A New, Longer-Lasting Type of Cholera Vaccine

A New, Longer-Lasting Type of Cholera Vaccine
News

A New, Longer-Lasting Type of Cholera Vaccine

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "A New, Longer-Lasting Type of Cholera Vaccine"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cholera, a diarrheal disease caused by the highly transmissible bacteria Vibrio cholerae, kills tens of thousands of people each year worldwide.


Current vaccines last only 2–5 years, and they don’t work very well in young children. Now, researchers reporting in ACS Infectious Diseases have developed a new type of cholera vaccine consisting of polysaccharides displayed on virus-like particles. The vaccine generated long-lasting antibody responses against V. cholerae in mice.


Current cholera vaccines contain killed or weakened V. cholerae bacteria and are administered orally. They offer the lowest level and duration of protection in young children, who are commonly affected by cholera in endemic countries. The immune system produces antibodies against the O-specific polysaccharide (OSP) on the surface of V. cholerae, but this polysaccharide in isolation does not generate a strong, long-lasting immune response. Peng Xu, Edward Ryan, Xuefei Huang and colleagues wondered if attaching OSP to virus-like particles could induce stronger, longer-lasting immunity.


So the researchers developed a method to efficiently link multiple copies of OSP to Qβ, a virus-like particle that infects bacteria. The modified virus-like particles were recognized by antibodies in blood taken from recovering cholera patients, but not from patients with typhoid, another bacterial disease. Next, the team immunized mice with Qβ-OSP, observing that three doses caused a strong antibody response that persisted at least 265 days after the first dose. The immunized mice had antibodies that recognized the OSP from the natural lipopolysaccharide of V. cholerae. When the researchers mixed serum antibodies from the mice with other immune system proteins that kill bacteria and with live V. cholerae, antibodies from two of the five mice triggered more bacterial death than those from mice immunized with Qβ alone. The virus-like particle could mimic natural bacteria by presenting multiple copies of OSP on its surface, the researchers say, and it warrants further evaluation as a next-generation cholera vaccine.


Reference: Mukherjee Angana, Crochetière Marie-Ève, Sergerie Audrey, et al. A phosphoinositide-binding protein acts in the trafficking pathway of hemoglobin in the malaria parasite Plasmodium falciparum. mBio. 0(0):e03239-21. doi: 10.1128/mbio.03239-21.


This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.


Advertisement